Expression of lymphoid enhance factor 1 in acute myelogenous leukemia patients with intermediate-risk and its clinical significance
10.3760/cma.j.issn.1009-9921.2017.03.008
- VernacularTitle:淋巴增强因子1在中危急性髓系白血病患者中的表达及其临床意义
- Author:
Guihua ZHANG
;
Jinge XU
;
Qiurong ZHANG
;
Lingsong CHEN
;
Kaige LIU
;
Jinyan WU
- Keywords:
Leukemia;
myeloid;
acute;
Polymerase chain reaction;
Lymphoid enhance factor 1;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2017;26(3):156-160
- CountryChina
- Language:Chinese
-
Abstract:
Objective To quantitatively analyze the mRNA expression level of lymphoid enhance factor 1 (LEF-1) in bone marrow mononuclear cells of patients with acute myeloid leukemia (AML) at intermediate-risk after initial diagnosis and chemotherapy, and to analyze its clinical significance. Methods The real-time fluorescence quantitative polymerase chain reaction (RT-PCR) was used to measure the expression level of LEF-1 gene in AML patients at intermediate-risk after initial diagnosis and chemotherapy, and its relationship with effectiveness and survival were analyzed. Results The LEF-1 mRNA level in preliminarily diagnosed patients with AML was significantly higher than that in control arm [0.00519 (0.00015-0.09207) vs. 0.00101 (0.00009-0.00233)], and the difference was statistically significant (u=134.50, P<0.01). The LEF-1 mRNA level in patients after chemotherapy was significantly declines as compared to that in patients before chemotherapy [0.00107 (0.00008 - 0.00744) vs. 0.00519 (0.00015 - 0.09207)], and the difference was statistically significant (u= 317.00, P< 0.01) and LEF-1 mRNA expression level before chemotherapy in complete remission (CR) patients was significantly higher than that in non-CR patients [(0.01108 (0.00164 - 0.09207) vs. 0.00110 (0.00015 - 0.00916)], and the difference was statistically significant (u=19.00, P<0.01). High LEF-1 expression predicted a significantly better overall survival in AML patients with intermediate-risk cytogenetics (χ2= 4.549, P= 0.033). Conclusions LEF-1 may be involved in the development and progression of AML at intermediate-risk patients and is closely related to tumor burden and treatment efficacy. LEF-1 may be a good predictor of better prognosis and a novel target for therapeutic effect.
